Anti-Bundibugyo Ebolavirus; GP1 (Clone BDBV-43)-Purified No Carrier Protein
Produktgrößen
250µg
£583,00
12-8194-250UG
1 mg
£812,00
12-8194-1MG
Über dieses Produkt
- SKU:
- 12-8194
- Anwendung:
- Electron Microscopy
- translate.label.attr.clone:
- BDBV-43
- Klonalität:
- Monoclonal
- Weitere Details:
- Specificity: BDBV-43 activity is directed against the glycan cap of the GP1 subunit of Bundibugyo ebolavirus (BDBV); Zaire ebolavirus (EBOV); and Sudan ebolavirus (SUDV) glycoprotein. Antigen Distribution: Ebola virus glycoprotein is a surface protein expressed on the virus envelope. Background: Ebola virus is a member of the Filoviridae family that causes severe disease in humans with a mortality rate of 25-90%1. Three Ebola species are responsible for lethal outbreaks: Zaire ebolavirus (EBOV); Bundibugyo ebolavirus (BDBV); and Sudan ebolavirus (SUDV). The Ebola virus envelope contains a single surface glycoprotein (GP) which is responsible for viral attachment to the host cell; endosomal entry; and membrane fusion1. GP is composed of two subunits; GP1 and GP2. GP1 has a heavily glycosylated mucin-like domain and a glycan cap. GP2 contains the internal fusion loop; transmembrane domain; and stalk. GP is the major target of neutralizing monoclonal antibody (mAb) and vaccine design against Ebola virus. mAbs targeting GP1 are capable of neutralizing all known filovirus GPs2;3. A pan-Ebola virus mAb is highly desirable to protect against future outbreaks. BDBV-43 is a glycan cap mAb isolated from B cells of a survivor of the 2007 Uganda BDBV outbreak3. Peripheral blood mononuclear cells from the survivor were transformed with Epstein-Barr virus; CpG; and additional supplements. Subsequently; cell supernatants were screened by ELISA for binding to GPs from BDBV; EBOV; or MARV filoviruses. Positive cells were fused with HMMA2.5 myeloma cells by electrofusion and cloned by single-cell fluorescence-activated cell sorting. In binding and neutralization assays; BDBV-43 binds to and neutralizes BDBV; EBOV and SUDV. BDBV-43 also binds BDBV-secreted GP (sGP)4. BDBV-43 is defined as a neutralizing antibody because it has a half-maximal inhibitory concentration value of < 10µg /mL3. Epitope mapping of GP1 shows that L273 is a critical binding residue for BDBV-433;4. Cryo-EM structures show that the BDBV-43 CDRH2 loop primarily binds along the ?17 strand from residues 268-280; with the majority of contacts around W2754.
- Host:
- HEK293
- Isotyp:
- Human IgG1k
- Aufreinigung:
- Purity: >=90% monomer by analytical SEC and SDS-Page Preparation: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are pu
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- This antibody may be stored sterile as received at 2-8[o]C for up to one month. For longer term storage; aseptically aliquot in working volumes without diluting and store at
- Hersteller:
- Abeomics
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules
- Datenblatt des Herstellers:download_pdf.php